top of page

Biopharma Daily Stock Updates - 03/30/22

$XBI $90.68 | -3.07%


 

Covid Updates

$CYDY +0.8% CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program source



Pipeline Updates

$ELOX +10.0% Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome source


$PTCT -4.0% PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease source


$AKBA -66.0% Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients source


$ANIX +1.3% Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center source

$ACIU -6.5% AC Immune KOL Webinar on First Clinical Proof of Concept for Alpha-synuclein Diagnostic Shows Breakthrough Potential for Neurodegenerative diseases. source


$GRAY -3.1% Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023. source


$REPL +2.0% Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies. source


$DSGN -2.9% Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia. source



Business Updates

$COLL -1.1% Collegium Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation. source

 

Posted by FS/JM

0 comments

Comments


bottom of page